Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-028413

Ocera Therapeutics, Inc. · OCRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Anne Vanlent
Director
Period of report
Dec 11, 2017
Accepted (ET)
Dec 11, 2017 · 3:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274644

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3Dec 11, 2017D12,500$1.52D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F4,F5,F6$2.26Dec 11, 2017D12,500D—Jun 13, 2026Common Stock12,5000D
Stock Option (Right to Buy)F4,F5,F7$7.85Dec 11, 2017D20,000D—Dec 19, 2023Common Stock20,0000D
Stock Option (Right to Buy)F4,F5,F8$3.76Dec 11, 2017D10,000D—Jun 17, 2025Common Stock10,0000D
Stock Option (Right to Buy)F4,F5,F9$48.00Dec 11, 2017D2,083D—Apr 19, 2021Common Stock2,0830D
Stock Option (Right to Buy)F4,F5,F10$50.88Dec 11, 2017D2,652D—Aug 7, 2022Common Stock2,6520D
Stock Option (Right to Buy)F4,F5,F11$7.84Dec 11, 2017D10,000D—Jun 11, 2024Common Stock10,0000D

Explanation of responses